{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:25:36Z","timestamp":1761625536434,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.dld.2022.03.001","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T19:15:10Z","timestamp":1648322110000},"page":"747-754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1831-6145","authenticated-orcid":false,"given":"Emeric","family":"Boisteau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Boulahssass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Paillaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lopez-Trabada Ataz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis-Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dld.2022.03.001_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.dld.2022.03.001_bib0002","first-page":"414","article-title":"A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer","volume":"30","author":"Rokkas","year":"2017","journal-title":"Ann Gastroenterol"},{"issue":"7","key":"10.1016\/j.dld.2022.03.001_bib0003","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2036.2007.03268.x","article-title":"Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type","volume":"25","author":"Takenaka","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.03.001_bib0004","unstructured":"SPF. Survie des personnes atteintes de cancer en France m\u00e9tropolitaine 1989-2018 - Estomac [Internet]. [cited 2021 Jan 23]; Available from: \/import\/survie-des-personnes-atteintes-de-cancer-en-france-metropolitaine-1989-2018-estomac"},{"issue":"suppl 5","key":"10.1016\/j.dld.2022.03.001_bib0005","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.dld.2022.03.001_bib0006","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9742","key":"10.1016\/j.dld.2022.03.001_bib0007","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dld.2022.03.001_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.respe.2013.11.073","article-title":"Cancer incidence and mortality in France over the 1980\u20132012 period: solid tumors","volume":"62","author":"Binder-Foucard","year":"2014","journal-title":"Rev D\u00e9pid\u00e9miol Sant\u00e9 Publique"},{"key":"10.1016\/j.dld.2022.03.001_bib0009","unstructured":"Cancer Statistics Review, 1975-2013 - previous version - SEER cancer statistics review [Internet]. SEER. [cited 2021 May 7]; Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2013\/index.html"},{"issue":"8","key":"10.1016\/j.dld.2022.03.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105137","article-title":"Nutritional status in community-dwelling elderly in France in urban and rural areas","volume":"9","author":"Torres","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2022.03.001_bib0011","unstructured":"Strat\u00e9gie de prise en charge en cas de d\u00e9nutrition prot\u00e9ino-\u00e9nerg\u00e9tique chez la personne \u00e2g\u00e9e [Internet]. Haute Aut. Sant\u00e9. [cited 2021 Aug 2]; Available from: https:\/\/www.has-sante.fr\/jcms\/c_546549\/fr\/strategie-de-prise-en-charge-en-cas-de-denutrition-proteino-energetique-chez-la-personne-agee."},{"issue":"1","key":"10.1016\/j.dld.2022.03.001_bib0012","first-page":"99","article-title":"Epidemiology of neurocognitive disorders in France","volume":"17","author":"Rochoy","year":"2019","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"7","key":"10.1016\/j.dld.2022.03.001_bib0013","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0895-4356(00)00368-1","article-title":"Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: the FINE study (Finland, Italy, Netherlands, Elderly)","volume":"54","author":"Menotti","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.dld.2022.03.001_bib0014","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1200\/JCO.2012.42.9894","article-title":"Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients","volume":"31","author":"Aparicio","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.dld.2022.03.001_bib0015","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"10.1016\/j.dld.2022.03.001_bib0016","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.dld.2022.03.001_bib0017","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1634\/theoncologist.2019-0166","article-title":"Inclusion of older patients with cancer in clinical trials: the SAGE prospective multicenter cohort survey","volume":"24","author":"Canou\u00ef-Poitrine","year":"2019","journal-title":"Oncologist"},{"issue":"32","key":"10.1016\/j.dld.2022.03.001_bib0018","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","article-title":"Improving the evidence base for treating older adults with cancer: American society of clinical oncology statement","volume":"33","author":"Hurria","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.dld.2022.03.001_bib0019","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2022.03.001_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.dld.2022.03.001_bib0021","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"10.1016\/j.dld.2022.03.001_bib0022","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"33","key":"10.1016\/j.dld.2022.03.001_bib0023","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2015.60.7465","article-title":"Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium","volume":"33","author":"Shah","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10184","key":"10.1016\/j.dld.2022.03.001_bib0024","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.dld.2022.03.001_bib0025","unstructured":"JFHOD | SNFGE.org Soci\u00e9t\u00e9 savante m\u00e9dicale fran\u00e7aise d'h\u00e9pato-gastroent\u00e9rologie et d'oncologie digestive [Internet]. [cited 2021 Aug 3]; Available from: https:\/\/www.snfge.org\/content\/metestomac-analyse-finale-dune-cohorte"},{"issue":"15","key":"10.1016\/j.dld.2022.03.001_bib0026","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"13","key":"10.1016\/j.dld.2022.03.001_bib0027","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"35","key":"10.1016\/j.dld.2022.03.001_bib0028","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2022.03.001_bib0029","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.dld.2022.03.001_bib0030","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9911","key":"10.1016\/j.dld.2022.03.001_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.dld.2022.03.001_bib0032","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.dld.2022.03.001_bib0033","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jgh.14007","article-title":"Age does not influence efficacy of ramucirumab in advanced gastric cancer: subgroup analyses of REGARD and RAINBOW","volume":"33","author":"Muro","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"3_Part_1","key":"10.1016\/j.dld.2022.03.001_bib0034","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living1","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"12","key":"10.1016\/j.dld.2022.03.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1016\/j.dld.2022.03.001_bib0036","first-page":"165","article-title":"Geriatric depression scale (GDS): recent evidence and development of a shorter version","volume":"5","author":"Sheikh","year":"1986","journal-title":"Clin Gerontol J Aging Ment Health"},{"issue":"5","key":"10.1016\/j.dld.2022.03.001_bib0037","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"2","key":"10.1016\/j.dld.2022.03.001_bib0038","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"10.1016\/j.dld.2022.03.001_bib0039","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4155\/bio-2020-0199","article-title":"A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations","volume":"13","author":"Desvignes","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.dld.2022.03.001_bib0040","first-page":"1645","article-title":"Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment","volume":"9","author":"Caillet","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"11","key":"10.1016\/j.dld.2022.03.001_bib0041","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10111","key":"10.1016\/j.dld.2022.03.001_bib0042","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.dld.2022.03.001_bib0043","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10142","key":"10.1016\/j.dld.2022.03.001_bib0044","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"10294","key":"10.1016\/j.dld.2022.03.001_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.dld.2022.03.001_bib0046","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/ijc.30018","article-title":"Clinical significance of circulating plasma DNA in gastric cancer","volume":"138","author":"Fang","year":"2016","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.dld.2022.03.001_bib0047","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bjc.2014.609","article-title":"Monitoring gastric cancer progression with circulating tumour DNA","volume":"112","author":"Hamakawa","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.dld.2022.03.001_bib0048","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00280-018-3560-5","article-title":"Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer","volume":"82","author":"Smit","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.dld.2022.03.001_bib0049","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-017-3380-z","article-title":"Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial","volume":"80","author":"Cohn","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.dld.2022.03.001_bib0050","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-16-0895","article-title":"Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer","volume":"16","author":"Tabernero","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.dld.2022.03.001_bib0051","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-015-0361-4","article-title":"Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics","volume":"55","author":"Gill","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.dld.2022.03.001_bib0052","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-016-0406-3","article-title":"Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients","volume":"55","author":"Caulet","year":"2016","journal-title":"Clin Pharmacokinet"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:18:32Z","timestamp":1761625112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1590865822002067"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.03.001","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}